Form 4: Beta Bionics CFO Stephen Feider Reports Stock and Option Awards

Stephen Feider, CFO of Beta Bionics, reports the acquisition of restricted stock units and stock options.

Summary

• Stephen Feider, the Chief Financial Officer of Beta Bionics, Inc. [BBNX], filed a Form 4 on March 3, 2025.
• The report details changes in his beneficial ownership of the company's securities.
• On February 27, 2025, Feider acquired 47,000 shares of common stock through a restricted stock unit award and was granted an option to purchase 71,000 shares.
• The restricted stock units were granted under the Issuer's 2025 Equity Incentive Plan.
• The options have an exercise price of $19.91 and vest in 36 equal monthly installments starting February 27, 2025, expiring on February 26, 2035.
• Following these transactions, Feider directly owns 47,000 shares of common stock and options for 71,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock and option grants. It's a standard practice and doesn't necessarily indicate positive or negative sentiment about the company's future performance.

Positives

• The grant of restricted stock units and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule of the options (36 months) encourages long-term commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• The stock and option awards align the CFO's interests with those of the shareholders, potentially incentivizing him to work towards increasing shareholder value.

Key Dates